The native hormone somatostatin plays an important role in vivo by acting on multiple targets via a family of five receptors to produce a broad spectrum of biological effects. Some peptide analogs of this enzyme are widely used in clinical practice. However, their clinical efficacy is limited because of some disadvantages. In this respect, the search for new drugs of this type is a critical task. In this review, we have summarized trends in the synthesis and biological effects of peptide somatostatin analogs since 1978 and future prospects for the development of these anticancer drugs.
Similar content being viewed by others
References
W. Vale, P. Brazeau, G. Grant, et al., C. R. Hebd. Seances Acad. Sci., Ser. D, 275(25), 2913 – 2916 (1972).
P. Brazeau, W. Vale, R. Burgus, et al., Science, 179(4068), 77 – 79 (1973).
L. Pradayrol, H. Jornvall, V. Mutt, and A. Ribet, FEBS Lett., 109(1), 55 – 58 (1980).
S. Reichlin, N. Engl. J. Med., 309(25), 1556 – 1563 (1983).
T. L. Aleinikova, L. V. Avdeeva, and L. E. Andrianova, Biochemistry [in Russian], E. S. Severin (ed.), GEOTAR-Media, Moscow (2009), pp. 250 – 258.
I. I. Dedov, G. A. Mel'nichenko, and V. F. Fadeev, Endocrinology [in Russian], GEOTAR-Media, Moscow (2007), pp. 50 – 57.
L. Buscail, F. Vernejoul, P. Faure, et al., Ann. Endocrinol., 63(2), 13 – 18 (2002).
G. Olias, S. Viollet, H. Kusserow, et al., J. Neurochem., 89(5), 1057 – 1091 (2004).
M. Appetecchia and R. Baldelli, J. Exp. Clin. Cancer Res., 29:19, 1 – 12 (March, 2010).
A. Nagy and A. V. Schally, Curr. Pharm. Des., 11(9), 1167 – 1180 (2005).
A. Kleemann, J. Engel, B. Kutscher, and D. Reichert, Pharmaceutical Substances: Syntheses, Patents, Applications, 5th Ed., Thieme, Germany (2009), pp. 994 – 996.
R. Barrie, E. A. Woltering, H. Hajarizadeh, et al., J. Surg. Res., 55(4), 446 – 450 (1993).
N. G. de la Torre, J. A. H. Wass, and H. E. Turner, Clin. Endocrinol. (Oxford, U. K.), 57(4), 425 – 441 (2002).
R. L. Adams, I. P. Adams, S. W. Lindow, et al., Br. J. Cancer, 92(8), 1493 – 1498 (2005).
M. Kilian, J. I. Gregor, I. Heukamp, et al., Clin. Exp. Metastasis, 26(7), 719 – 727 (2009).
Y. C. Patel, Front. Neuroendocrinol., 20(3), 157 – 198 (1999).
W. Meyerhof, Rev. Physiol., Biochem. Pharmacol., 133, 55 – 108 (1998).
D. Rosskopf, M. Schurks, I. Manthey, et al., Am. J. Physiol.: Cell Physiol., 284(1), 179 – 190 (2003).
J. P. Hannon, C. Nunn, B. Stolz, et al., J. Mol. Neurosci., 18(1 – 2), 15 – 27 (2002).
G. Weckbecker, I. Lewis, R. Albert, et al., Nat. Rev. Drug Discovery, 2(12), 999 – 1017, Supplementary information (2003).
C. Bruns, I. Lewis, U. Briner, et al., Eur. J. Endocrinol., 146(5), 707 – 716 (2002).
J. C. Reubi, B. Waser, J. C. Schaer, and J. A. Laissue, Eur. J. Nucl. Med., 28(7), 836 – 846 (2001).
M. C. Champaneria, I. M. Modlin, I. Latich, et al., Molecular Targeting in Oncology, Humana Press, Totowa (2008), pp. 585 – 637.
I. M. Chapman, A. Helfgott, and J. O. Willoughby, J. Endocrinol., 128(3), 369 – 374 (1991).
A. V. Schally, Cancer Res., 48(24), 6977 – 6985 (1988).
W. Vale, J. Rivier, N. Ling, and M. Brown, Metab., Clin. Exp., 27(9), 1391 – 1401 (1978).
D. F. Veber, R. M. Freidinger, D. S. Perlow, et al., Nature, 292(5818), 55 – 58 (1981).
A. G. Harris, Gut, 35(Suppl. 3), S1-S4 (1994).
J. Epelbaum, Prog. Neurobiol., 27(1), 63 – 100 (1986).
R. Z. Cai, B. Szoke, R. Lu, et al., Proc. Natl. Acad. Sci. USA, 83(6), 1896 – 1900 (1986).
R. Z. Cai, T. Karashima, J. Guoth, et al., Proc. Natl. Acad. Sci. USA, 84(6), 2502 – 2506 (1987).
I. Gottesman, J. Tobert, R. Vandlen, and J. Gerich, Life Sci., 38(24), 2211 – 2219 (1986).
G. Melen-Mucha and M. Pawlikowski, Somatostatin Analogs in Diagnostics and Therapy, Landes Bioscience, Austin (2007), pp. 91 – 100.
W. Bauer, U. Briner, W. Doepfner, et al., Life Sci., 31(11), 1133 – 1140 (1982).
A. J. Czernik and B. Petrack, J. Biol. Chem., 258(9), 5525 – 5530 (1983).
D. F. Veber, R. Saperstein, R. F. Nutt, et al., Life Sci., 34(14), 1371 – 1378 (1984).
J. E. Taylor, A. E. Bogden, J. P. Moreau, and D. H. Coy, Biochem. Biophys. Res. Commun., 153(1), 81 – 86 (1988).
H. A. Schmid and A. P. Silva, J. Endocrinol. Invest., 28(11 Suppl. International), 28 – 35 (2005).
P. M. Stewart, K. F. Kane, S. E. Stewart, et al., J. Clin. Endocrinol. Metab., 80(11), 3267 – 3272 (1995).
E. Bajetta, G. Procopio, L. Catena, et al., Cancer, 107(10), 2474 – 2481 (2006).
H. Kessler, Angew. Chem., Int. Ed., 21(7), 512 – 523 (1982).
C. Gilon, M. Huenges, B. Matha, et al., J. Med. Chem., 41(6), 919 – 929 (1998).
E. Falb, Y. Salitra, T. Yechezkel, et al., Biooorg. Med. Chem., 9(12), 3255 – 3264 (2001).
M. Afargan, E. T. Janson, G. Geleman, et al., Endocrinology, 142(1), 477 – 486 (2001).
A. Carotenuto, D. D’Addona, E. Rivalta, et al., Lett. Org. Chem., 2(3), 274 – 279 (2005).
D. D’Addona, A. Carotenuto, E. Novellino, et al., J. Med. Chem., 51(3), 512 – 520 (2008).
A. Di Cianni, A. Carotenuto, D. Brancaccio, et al., J. Med. Chem., 53(16), 6188 – 6197 (2010).
P. Martin-Gago, R. Ramon, E. Aragon, et al., Bioorg. Med. Chem. Lett., 24(1), 103 – 107 (2014).
G. Fridkin, T. Maina, B. A. Nock, et al., Bioorg. Med. Chem., 19(2), 798 – 806 (2011).
J. Chatterjee, C. Gilon, A. Hoffman, and H. Kessler, Acc. Chem. Res., 41(10), 1331 – 1342 (2008).
J. Chatterjee, B. Laufer, J. G. Beck, et al., ACS Med. Chem. Lett., 2(7), 509 – 514 (2011).
E. Biron, J. Chatterjee, O. Ovadia, et al., Angew. Chem., Int. Ed., 47(14), 2595 – 2599 (2008).
W. G. Rajeswaran, S. J. Hocart, W. A. Murphy, et al., J. Med. Chem., 44(9), 1416 – 1421 (2001).
J. Erchegyi, R. Cescato, B.Waser, et al., J. Med. Chem., 54(17), 5981 – 5987 (2011).
J. Erchegyi, B. Penke, L. Simon, et al., J. Med. Chem., 46(26), 5587 – 5596 (2003).
J. C. Reubi, J. C. Schaer, S. Wenger, et al., Proc. Natl. Acad. Sci. USA, 97(25), 13973 – 13978 (2000).
J. Erchegyi, B. Waser, J. C. Schaer, et al., J. Med. Chem., 46(26), 5597 – 5605 (2003).
G. Liapakis, C. Hoeger, J. Rivier, and T. Reisine, J. Pharmacol. Exp. Ther., 276(3), 1089 – 1094 (1996).
J. Erchegyi, R. Cescato, C. R. R. Grace, et al., J. Med. Chem., 52(9), 2733 – 2746 (2009).
R. Ramon, P. Martin-Gago, X. Verdaguer, et al., ChemBioChem, 12(4), 625 – 631 (2011).
S. Staykova, E. Naydenova, D. Wesselinova, et al., Protein Pept. Lett., 19(12), 1257 – 1262 (2012).
S. T. Staykova, B. D. Mihaylova, I. G. Goshev, et al., Bulg. Chem. Commun., 44(3), 233 – 237 (2012).
S. J. Hocart, R. Jain, W. A. Murphy, et al., J. Med. Chem., 42(11), 1863 – 1871 (1999).
T.-A. Tran, R.-H. Mattern, M. Afargan, et al., J. Med. Chem., 41(15), 2679 – 2685 (1998).
R. H. Mattern, S. B. Moore, T. A. Tran, et al., Tetrahedron, 56(50), 9819 – 9831 (2000).
C. Caumes, T. Hjelmgaard, O. Roy, et al., MedChemComm, 3(12), 1531 – 1535 (2012).
K. Gademann, T. Kimmerlin, D. Hoyer, and D. Seebach, J. Med. Chem., 44(15), 2460 – 2468 (2001).
K. Gademann and D. Seebach, Helv. Chim. Acta, 84(10), 2924 – 2937 (2001).
A. Nagy, A. V. Schally, G. Halmos, et al., Proc. Natl. Acad. Sci. USA, 95(4), 1794 – 1799 (1998).
S. Radulovic, A. Nagy, B. Szoke, and A. V. Schally, Cancer Lett., 62(3), 263 – 271 (1992).
A. Saveanu, E. Lavaque, G. Gunz, et al., J. Clin. Endocrinol. Metab., 87(12), 5545 – 5552 (2002).
D. Ferone, A. Saveanu, M. D. Culler, et al., Eur. J. Endocrinol., 156, S23-S28 (2007).
G. Keri, J. Erchegyi, A. Horvath, et al., Proc. Natl. Acad. Sci. USA, 93(22), 12513 – 12518 (1996).
G. Keri, I. Mezo, Z. Vadasz, et al., Pept. Res., 6(5), 281 – 288 (1993).
B. Szende and G. Keri, Anti-Cancer Drugs, 14(8), 585 – 588 (2003).
T. Vantus, G. Keri, Z. Krivickiene, et al., Cell. Signalling, 13(10), 717 – 725 (2001).
A. Miyazaki, Y. Tsuda, S. Fukushima, et al., J. Med. Chem., 51(16), 5121 – 5124 (2008).
I. Kuriyama, A. Miyazaki, Y. Tsuda, et al., Bioorg. Med. Chem., 21(2), 403 – 411 (2013).
I. Kuriyama, A. Miyazaki, Y. Tsuda, et al., Anticancer Res., 30(12), 4841 – 4850 (2010).
L. I. Smirnova, S. V. Ustinkina, A. P. Smirnova, et al., RU Pat. No. 2,254,139, Jun. 20, 2005; Chem. Abstr., 143, 53473 (2005).
I. Yu. Kubasova, L. M. Borisova, M. P. Kiseleva, et al., Ross. Bioterapevticheskii Zh., 5(3), 128 – 133 (2006).
Z. S. Shprakh, I. V. Yartseva, E. V. Ignat'eva, et al., Khim-farm. Zh., 48(3), 19 – 22 (2014); Pharm. Chem. J., 48(3), 159 – 162 (2014).
A. N. Balaev, V. N. Osipov, V. E. Fedorov, et al., Ross. Bioterapevticheskii Zh., 11(4), 47 – 53 (2012).
A. N. Balaev, V. N. Osipov, V. E. Fedorov, et al., Ross. Bioterapevticheskii Zh., 12(3), 57 – 60 (2013).
E. I. Mikhaevich and M. A. Krasil'nikov, Byull. Eksp. Biol. Med., 154(11), 629 – 632 (2012).
Acknowledgments
The review was supported by the Russian Federation Ministry of Education and Science (under the auspices of Contract No. 14.576.21.0044).
Author information
Authors and Affiliations
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 49, No. 6, pp. 3 – 9, June, 2015.
Rights and permissions
About this article
Cite this article
Balaev, A.N., Osipov, V.N. & Khachatryan, D.S. Synthetic Peptide Analogs of Somatostatin: Trends in the Synthesis of and Prospects in the Search for New Anticancer Drugs. Pharm Chem J 49, 345–351 (2015). https://doi.org/10.1007/s11094-015-1284-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-015-1284-y